FibroGen (FGEN) Revenue & Revenue Breakdown
FibroGen Revenue Highlights
Latest Revenue (Y)
$147.75M
Latest Revenue (Q)
$50.64M
Main Segment (Y)
Drug Product Revenue
Main Geography (Y)
CHINA
FibroGen Revenue by Period
FibroGen Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $147.75M | 4.99% |
| 2022-12-31 | $140.73M | -40.19% |
| 2021-12-31 | $235.31M | 33.46% |
| 2020-12-31 | $176.32M | -31.28% |
| 2019-12-31 | $256.58M | 20.48% |
| 2018-12-31 | $212.96M | 69.46% |
| 2017-12-31 | $125.67M | -30.02% |
| 2016-12-31 | $179.58M | -0.69% |
| 2015-12-31 | $180.83M | 31.41% |
| 2014-12-31 | $137.60M | 34.68% |
| 2013-12-31 | $102.17M | 54.96% |
| 2012-12-31 | $65.93M | - |
FibroGen generated $147.75M in revenue during NA 2023, up 4.99% compared to the previous quarter, and up 69.38% compared to the same period a year ago.
FibroGen Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $50.64M | -9.41% |
| 2024-03-31 | $55.90M | 105.99% |
| 2023-12-31 | $27.14M | -32.38% |
| 2023-09-30 | $40.13M | -9.44% |
| 2023-06-30 | $44.32M | 22.56% |
| 2023-03-31 | $36.16M | 5.22% |
| 2022-12-31 | $34.37M | 118.41% |
| 2022-09-30 | $15.73M | -47.21% |
| 2022-06-30 | $29.81M | -51.00% |
| 2022-03-31 | $60.83M | 267.69% |
| 2021-12-31 | $16.54M | -89.39% |
| 2021-09-30 | $155.97M | 540.18% |
| 2021-06-30 | $24.36M | -36.60% |
| 2021-03-31 | $38.43M | -40.88% |
| 2020-12-31 | $65.00M | 47.62% |
| 2020-09-30 | $44.03M | 2.67% |
| 2020-06-30 | $42.89M | 75.76% |
| 2020-03-31 | $24.40M | 206.01% |
| 2019-12-31 | $7.97M | -75.96% |
| 2019-09-30 | $33.17M | -82.68% |
| 2019-06-30 | $191.57M | 702.77% |
| 2019-03-31 | $23.86M | -77.92% |
| 2018-12-31 | $108.05M | 272.25% |
| 2018-09-30 | $29.03M | -33.96% |
| 2018-06-30 | $43.95M | 37.67% |
| 2018-03-31 | $31.93M | -24.90% |
| 2017-12-31 | $42.51M | 55.87% |
| 2017-09-30 | $27.27M | -5.95% |
| 2017-06-30 | $29.00M | 7.83% |
| 2017-03-31 | $26.89M | -15.73% |
| 2016-12-31 | $31.91M | 6.01% |
| 2016-09-30 | $30.10M | -66.28% |
| 2016-06-30 | $89.28M | 215.68% |
| 2016-03-31 | $28.28M | 15.71% |
| 2015-12-31 | $24.44M | 25.10% |
| 2015-09-30 | $19.54M | -83.79% |
| 2015-06-30 | $120.55M | 639.66% |
| 2015-03-31 | $16.30M | 1.20% |
| 2014-12-31 | $16.11M | 17.88% |
| 2014-09-30 | $13.66M | -84.81% |
| 2014-06-30 | $89.96M | 403.23% |
| 2014-03-31 | $17.88M | 44.28% |
| 2013-12-31 | $12.39M | -82.61% |
| 2013-09-30 | $71.25M | - |
FibroGen generated $50.64M in revenue during Q2 2024, up -9.41% compared to the previous quarter, and up 140.04% compared to the same period a year ago.
FibroGen Revenue Breakdown
FibroGen Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Drug Product Revenue | $18.75M | $11.09M | $962.00K | $8.91M | - |
| Product | - | - | - | $89.03M | $-34.62M |
| A P I Product | - | - | - | - | $-36.32M |
| Drug Product | - | - | - | - | $2.80M |
FibroGen's latest annual revenue breakdown by segment (product or service), as of Dec 23: Drug Product Revenue (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $46.21M | $30.54M | $29.39M | $35.92M | $27.90M | $19.83M | $5.37M | $579.00K | - | - | - | - | - | - | - | - | - |
| Drug Product Revenue | $-262.00K | $24.49M | $1.05M | $1.32M | $14.27M | $2.11M | $6.48M | $1.09M | $7.59M | $1.13M | $8.48M | $686.00K | $8.24M | - | - | - | - |
| License | - | - | $2.65M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Royalty | - | - | - | - | - | - | - | $200.00K | - | - | - | - | - | - | - | - | - |
FibroGen's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (100.57%), and Drug Product Revenue (-0.57%).
FibroGen Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Europe | $9.55M | $33.82M | $131.24M | $67.16M | $132.40M |
| CHINA | $109.38M | $84.63M | $55.64M | $72.50M | - |
| UNITED STATES | $12.96M | $12.52M | $46.12M | - | - |
| JAPAN | $15.87M | $9.76M | $2.31M | $36.66M | - |
| All Other | - | - | - | - | $1.70M |
FibroGen's latest annual revenue breakdown by geography, as of Dec 23: CHINA (74.03%), JAPAN (10.74%), UNITED STATES (8.77%), and Europe (6.46%).
Quarterly Revenue by Country
| Country | Sep 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 |
|---|---|---|---|---|---|
| CHINA | $4.50M | $2.10M | $104.38M | $4.70M | $300.00K |
FibroGen's latest quarterly revenue breakdown by geography, as of Sep 24: CHINA (100.00%).
FibroGen Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BMRN | BioMarin Pharmaceutical | $2.42B | $733.87B |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| STRO | Sutro Biopharma | $153.73M | $25.71M |
| FGEN | FibroGen | $147.75M | $50.64M |
| ARDX | Ardelyx | $124.46M | $98.24M |
| MRUS | Merus | $43.95M | $11.77M |
| AGIO | Agios Pharmaceuticals | $26.82M | $8.96M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| MREO | Mereo BioPharma Group | $10.00M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.89M |
| FIXX | Q32 Bio | $1.16M | - |
| LYEL | Lyell Immunopharma | $130.00K | $34.00K |
| CGEM | Cullinan Oncology | - | - |
| VSTM | Verastem | - | $10.00M |
| AVRO | AVROBIO | - | - |
| PCVX | Vaxcyte | - | - |
| GOSS | Gossamer Bio | - | $9.48M |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| ZURA | Zura Bio | - | - |
| BMEA | Biomea Fusion | - | - |
| SNDX | Syndax Pharmaceuticals | - | $12.50M |
| LRMR | Larimar Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| AKRO | Akero Therapeutics | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |